TG Therapeutics Inc (TGTX) is scheduled to announce Q2 2021 earnings on Monday, 02 August 2021, before market open. Wallstreet estimates an EPS of $-0.55 and a revenue of $3.60 M in the upcoming results. Historically, TG Therapeutics Inc beated EPS estimates 26% of the times.
About TG Therapeutics Inc
TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. It also involves developing TG-1101 and TGR-1202 therapies targeting hematological malignancies. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY.